Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 6:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 2 Interventional Results available

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223
Conditions
Substance Use Disorders, Methamphetamine Abuse
Interventions
Intranasal Methamphetamine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Opioid Abuse (Disorder), Stimulant Use Disorders
Interventions
Patient Navigation
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Methamphetamine Abuse
Interventions
Affect Methamphetamine Treatment Program
Behavioral
Lead sponsor
Affect Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Prescription Drug Abuse (Not Dependent), Intentional Misuse
Interventions
Web-based placebo presentation, Web-based simulation active intervention
Other · Behavioral
Lead sponsor
Trinity College
Other
Eligibility
17 Years to 25 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Hartford, Connecticut • San Marcos, Texas • Laramie, Wyoming
Conditions
ADHD, Stimulant-Induced Euphoria
Interventions
SODAS MPH, Naltrexone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 30 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Abuse Potential of Istradefylline

NCT02609477
Conditions
Drug Abuse
Interventions
Istradefylline, Phentermine 45 mg, Placebo
Drug · Other
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
ADHD, Narcolepsy
Interventions
ADAIR 10 mg IR tablets, d-amphetamine sulfate, Placebo
Drug
Lead sponsor
Vallon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 3 Interventional Results available

Stimulant Abuser Groups to Engage in 12-Step

NCT00573183
Conditions
Drug Abuse
Interventions
STAGE-12, Treatment as Usual
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Jacksonville, Florida • Kaneohe, Hawaii • Columbus, Ohio + 7 more
Conditions
Drug Abuse, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
Interventions
Contingency Management, Non Contingent Control Condition
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

Study for Naltrexone on the Abuse Potential of Methylphenidate

NCT03769064
Conditions
Naltrexone, Methylphenidate Abuse
Interventions
Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421
Drug
Lead sponsor
Avekshan LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Overland Park, Kansas
Completed Not applicable Interventional Results available

Exercise as a Treatment for Substance Use Disorders Protocol

NCT01141608
Conditions
Stimulant Abuse and Dependence
Interventions
Vigorous Intensity High Dose Exercise, Health Education Intervention
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
9
States / cities
Denver, Colorado • Jacksonville, Florida • Cape Girardeau, Missouri + 6 more
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Recruiting No phase listed Observational Accepts healthy volunteers

Neurocognitive Abnormalities in Stimulant Abuse Among High-Risk Women

NCT05845333
Conditions
Stimulant Abuse, Criminal Behavior
Interventions
Decision task
Other
Lead sponsor
The Mind Research Network
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Methamphetamine-dependence, Substance Abuse
Interventions
Ibudilast 20mg, Ibudilast 50mg, Placebo oral tablet
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Completed Phase 2 Interventional Results available

New Medication Treatment for Stimulant Dependence

NCT00689572
Conditions
Cocaine Dependence
Interventions
Ondansetron, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Conditions
Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Substance Abuse
Interventions
Adderall
Drug
Lead sponsor
Jeffrey Newcorn
Other
Eligibility
7 Years to 12 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

Project neuroARTEMIS

NCT06814275
Conditions
Stimulant Use, Human Immunodeficiency Virus (HIV), Depression
Interventions
ARTEMIS, Contingency management for Antiretroviral (ARV) adherence
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 59 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed No phase listed Observational

Stimulant Use and Methylation in HIV

NCT05916989
Conditions
HIV Infections, Methamphetamine-dependence, Methamphetamine Abuse
Interventions
Not listed
Lead sponsor
Florida International University
Other
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Methamphetamine Abuse, Substance Use Disorders, Stimulant Dependence, Methamphetamine-dependence, Stimulant Use, Transcranial Magnetic Stimulation
Interventions
Real Repetitive transcranial magnetic stimulation, Sham Repetitive transcranial magnetic stimulation, Methamphetamine visual cues, Neutral visual cues
Device · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Conditions
PrEP Uptake, Stimulant Abuse, Adherence, Medication
Interventions
Pepped on PrEP Package
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alcohol Abuse, Cannabis Abuse, Major Depressive Disorder, Substance-Related Disorders
Interventions
Integrated Cognitive Behavioral Therapy, Twelve Step Facilitation Therapy
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
San Diego, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

NCT00617201
Conditions
Substance Abuse
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky